## GRANT ELIGIBILITY SUMMARY

**Eligibility criteria applicable to all grant categories:**

- Institutions must have a non-profit tax status to be eligible. Check Grant Criteria for International eligibility
- Applicants need **not** be U.S. citizens
- Other criteria or restrictions may apply; see individual grant mechanism guidelines for complete details

<table>
<thead>
<tr>
<th>Grant Type</th>
<th>Grant Description/Goal</th>
<th>PI Eligibility Criteria</th>
<th>Award Length</th>
<th>Annual Amt</th>
</tr>
</thead>
</table>
| ‘A’ Award                   | For the early independent career scientist who wants to establish a career in the field of pediatric oncology research. Ideal applicant has an original project, can demonstrate outstanding career development support from the institution, and has a strong future commitment to pediatric cancer investigation. | • Degree: M.D., Ph.D. or dual M.D., Ph.D. (D.O., MBBS or equivalent) and be within 5 years of first faculty position as Assistant Professor (Associate & Full Professors ineligible)  
  • Minimum 75% protected time for all research activities  
  • Applicants cannot have a K99/R00 or other independent PD/PI award (e.g. R01 or equivalent, P or U award) that has been funded or recommended for funding (i.e. will be funded) at the time of application.  
  • Current ALSF Young Investigator grantees may apply (Reach, Innovation, Phase I/II Infrastructure grant recipients ineligible) | 4 years (Conditional 5th year) | $200,000   |
| Bio-Therapeutic Impact Award| Support investigator-initiated clinical trials using biologic therapies, including but not limited to immunotherapy (including cell therapies), gene therapy and small molecules. This grant was initiated to accelerate the development of clinical trials for promising biologic approaches to treat childhood cancers. | • Track 1: Clinical trial support where all pre-clinical studies have been completed, an IND has been approved  
  • Track 2: pre-clinical bridge funding is available for one year to per IND enabling studies. The Principle Investigator will be responsible for the studies. Must have well-defined plan to complete IND submission to be approved within one year of the start of grant  
  • Demonstrates a track record of implementing novel biologic therapies  
  • Has experience executing and completing clinical trials that meet projected accrual targets in timely manner  
  • Must have a well-defined plan and time frame to complete trial enrollment  
  • Investigator(s) may be working within a consortium | 3 years | Pre-IND year: $100,000  
Clinical Trial Years: $500,000 |
<table>
<thead>
<tr>
<th>Grant Type</th>
<th>Grant Description/Goal</th>
<th>PI Eligibility Criteria</th>
<th>Award Length</th>
<th>Annual Amt</th>
</tr>
</thead>
</table>
| Center of Excellence        | Funds leading institutions with programs committed to developing and conducting early phase clinical trials for childhood cancer and with a pediatric oncology clinical pharmacology/developmental therapeutics program. The ultimate goal is to expedite the development of novel therapeutic approaches for pediatric malignancies by establishing robust Centers of Excellence in pediatric cancer drug development and through training the next generation of leaders in preclinical and clinical drug development. | • Invite only based on Institutions developmental therapeutics and clinical trial programs  
  • Funds must be used in the following manner:  
    • 50% of the funds must be used to enhance the awardee’s clinical trial infrastructure. These funds can be used to support clinical research assistants, protocol coordinators, nurse practitioners, research nurses, etc.  
    • The remaining 50% of funds will be used to support the training of physician scholars in drug development. These individuals will be named ALSF Scholars in Developmental Therapeutics and the institutions will be named ALSF Centers of Excellence. | 5 years      | $350,000         |
| Crazy 8 Initiative          | Supports research into innovative and rigorous approaches that directly address the most intractable issues in pediatric cancer research today. This award is designed to coalesce cross-disciplinary cores of scientists working collaboratively in order to accelerate the pace of new cure discovery.                                                                 | • Degree: M.D., Ph.D., or M.D./Ph.D. or equivalent and be appointed as faculty (or equivalent) at an academic institution.  
  • Investigators must have track record of publication and funding productivity.  
  • Applicant institutions may be based in the United States or abroad, and applicants need not be United States citizens. Funds must be granted to nonprofit institutions or organizations.  
  • Proposal should address at least one of the four Crazy 8 themes and at least one of the Crazy 8 disciplines.  
  • Collaboration and data sharing must be exhibited.                                                                                                                                                                                                 | 4 years      | $1-5 million     |
| Epidemiology Grant          | Support researchers who have a specific focus on the epidemiology, early detection or prevention of childhood cancer.                                                                                                                                                        | • Degree: M.D., Ph.D. or M.D./Ph.D.  
  • Faculty appointment: Assistant, Associate or Full Professor level  
  • Must have history of formal training, or track record in conducting research in a similar discipline                                                                                                                                                                       | 2 years      | $100,000         |
| Innovation Grants           | Critical and significant seed funding for experienced investigators with a novel and promising approach to finding causes and cures for childhood cancers.                                                                                                                                  | • Degree: M.D., Ph.D. or M.D./Ph.D.  
  • Must be established investigator, have a faculty appointment at academic Institution.  
  • Demonstrate publication & funding productivity in last 5 years                                                                                                                                                                                                                                                                   | 2 years      | $125,000         |
<table>
<thead>
<tr>
<th>Grant Type</th>
<th>Grant Description/Goal</th>
<th>PI Eligibility Criteria</th>
<th>Award Length</th>
<th>Annual Amt</th>
</tr>
</thead>
</table>
| Phase I/II Infrastructure   | Funds support Phase I and II clinical trials by funding infrastructure necessary to conduct these important studies. The aim of the grant is to help institutions build the capacity of their Phase I and II programs.                                | • Applications should originate from outstanding pediatric cancer centers with a strong track record of participation in Phase I and II clinical trials.  
• The Principal Investigator of the grant should have significant experience in conducting early phase clinical research studies.  
• Institutions which have completed an ALSF Program Infrastructure grant, may apply.                                                                                       | 5 years      | $125,000   |
|                             |                                                                                                           |                                                                                                           | Additional 5 years with Institution match                                                                                                                                            |             |            |
| Psychosocial Family Impact Grant | Support studies to explain and/or improve psychosocial outcomes of those affected by childhood cancer. This grant is designed to fund researchers who have novel approaches to understanding the psychosocial aspects of pediatric cancer and whose proposals will have clinically significant impact. | • Degree: Ph.D., Psy.D., M.D., D.O., Ed.D., D.N.P., or M.D./Ph.D.  
• Faculty appointment: full-time faculty appointment  
• Demonstrate productivity in the field of pediatric oncology:  
  • independent investigator  
  • grant funding (NIH or other foundation)  
  • peer-reviewed publications  
• Co-Principal Investigators are permitted:  
  • must demonstrate history of prior successful collaborations  
  • at least one Co-PI needs pediatric oncology expertise, others should have complimentary expertise | 3 years      | $100,000   |
| Psychosocial Launch Grant   | Supports early career researchers, within 7 years of receiving their terminal degree, to conduct studies to explain or improve psychosocial outcomes of those affected by childhood cancer.                                      | • Degree: Ph.D., Psy.D., M.D., D.O., Ed.D., D.N.P., or M.D./Ph.D.  
• Completed all formal training & hold full-time position that includes research devoted to pediatric cancer patients  
• Be within 7 years of receiving terminal degree  
• Must not hold independent NIH grant (R or P Award)  
• Research mentor identified must document involvement in design and execution, as well as training and mentorship | 2 years      | $50,000    |
<table>
<thead>
<tr>
<th>Grant Type</th>
<th>Grant Description/Goal</th>
<th>PI Eligibility Criteria</th>
<th>Award Length</th>
<th>Annual Amt</th>
</tr>
</thead>
</table>
| Reach Grant                        | To move hypothesis-driven research into the clinic by funding selected *late translational* studies. Preference to those research projects which will likely result in initiation of a clinical trial in two to three years. | • Applicants must be M.D., D.O., Ph.D. or M.D./Ph.D. or equivalent and be appointed as faculty (or equivalent) at an academic institution  
  • Applicants must have a demonstrated track record of pediatric cancer research with experience in translational research  
  • Multiple investigator applications that bring together pairs or teams of researchers with complementary expertise are encouraged  
  • A plan for clinical implementation of the concept and an overall clinical development plan for the therapeutic approach must be included with a projected timeline for the completing trial (note: this grant does not fund clinical trials) | 2 years      | $125,000   |
| RUNX1 Early Career Investigator Grant | To fund a new generation of translational and clinical researchers interested in researching strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with RUNX1-FPD. | • Must be within 5 years of first faculty appointment as an Assistant Professor or equivalent. Associate and Full Professors are ineligible.  
  • Degree: M.D., Ph.D. or dual M.D., Ph.D. (D.O., MBBS or equivalent).  
  • Minimum of 75% of applicant’s time during the award period must be allocated as protected time for all research activities.  
  • Must have research experience working in, and a deep understanding of, normal or malignant hematopoiesis and/or immunology  
  • Aims of research must be relevant to the ultimate goal of preventing hematologic malignant transformation in RUNX1-FPD. Proposals that seek to translate from bench to bedside will receive priority. | 3 years      | $60,000    |
| RUNX1 Familial Research Grant      | To fund research in strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with FPD/AML. | • Must have faculty appointment at academic institution  
  • Degree: M.D., D.O., Ph.D. or M.D./Ph.D.  
  • Have a record of publication & funding productivity in last 5 years  
  • Teams of researchers with complementary expertise may apply  
  • Projects should focus on leukemia caused by familial RUNX1 mutations rather than sporadic AML with somatic RUNX1 mutations. | 2 years      | $125,000   |
# GRANT ELIGIBILITY SUMMARY

<table>
<thead>
<tr>
<th>Grant Type</th>
<th>Grant Description/Goal</th>
<th>PI Eligibility Criteria</th>
<th>Award Length</th>
<th>Annual Amt</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single Cell Pediatric Cancer Atlas</td>
<td>ALSF seeks to build a Pediatric Cancer Atlas as an open resource for discovery with an initial goal of producing data that can be harmonized. ALSF seeks researchers to create datasets that profile pediatric cancers at a single-cell resolution level. Single-cell profiling can provide insights into the heterogeneity of cells in a tumor and the surrounding tumor microenvironment, as well as variability in the states of cancer cells, all of which can influence the cancer’s response to treatments.</td>
<td>• Applicants must have an MD, PhD, or MD/PhD or equivalent and be appointed as faculty (or equivalent) at an academic institution. • Applicants must have a track record of publication and funding productivity that demonstrates that the project can be accomplished by the investigators.</td>
<td>1 year</td>
<td>$100,000</td>
</tr>
<tr>
<td>Young Investigator Grant</td>
<td>Support scientists during their fellowship training or early stages of their pediatric oncology research career. Demonstration of outstanding mentorship and demonstration of a career plan that shows commitment to pediatric cancer investigation are critical components of a successful application.</td>
<td>• Degree: M.D., Ph. D. or dual M.D./Ph.D. • Applicants from accredited fellowship programs are automatically eligible for the duration of their training &amp; during their first three years at the Instructor level. All other applicants must be within five years from the granting of the last doctoral degree • Minimum 75% protected time for all research activities • Must not hold NIH independent or individual training grant (R/P or F/K type); K12 or T32 grants are permitted • Must apply with a research mentor who has a track record in pediatric oncology</td>
<td>3 years</td>
<td>$50,000</td>
</tr>
</tbody>
</table>